BioMarin Pharmaceutical Inc. (BMRN)

[ghmm]

I'd recommend listening to the Merrill Lynch conference to anyone who hasn't already and who follows BMRN.

JJ spent a lot of the time on BH4 Cardio Vascular and there was a Q&A period at the end.

I got the impression Phenoptin may be priced higher then, at least I, was expecting and perhaps even some analysts.

Everyone loves to speculate but my guess (no more) is BioMarin doesn't get bought out this year. Also keep in mind while the Uncontrolled Hypertension study results are do this month this is just a 2A study and the company has already indicated (assuming positive results) they'd do a 2B (dose ranging) study after. So my guess is the 2A would offer an idea at efficacy but not the clear picture on it.